Direkt zum Inhalt
Merck
  • IgSF9b regulates anxiety behaviors through effects on centromedial amygdala inhibitory synapses.

IgSF9b regulates anxiety behaviors through effects on centromedial amygdala inhibitory synapses.

Nature communications (2018-12-24)
Olga Babaev, Hugo Cruces-Solis, Carolina Piletti Chatain, Matthieu Hammer, Sally Wenger, Heba Ali, Nikolaos Karalis, Livia de Hoz, Oliver M Schlüter, Yuchio Yanagawa, Hannelore Ehrenreich, Holger Taschenberger, Nils Brose, Dilja Krueger-Burg
ZUSAMMENFASSUNG

Abnormalities in synaptic inhibition play a critical role in psychiatric disorders, and accordingly, it is essential to understand the molecular mechanisms linking components of the inhibitory postsynapse to psychiatrically relevant neural circuits and behaviors. Here we study the role of IgSF9b, an adhesion protein that has been associated with affective disorders, in the amygdala anxiety circuitry. We show that deletion of IgSF9b normalizes anxiety-related behaviors and neural processing in mice lacking the synapse organizer Neuroligin-2 (Nlgn2), which was proposed to complex with IgSF9b. This normalization occurs through differential effects of Nlgn2 and IgSF9b at inhibitory synapses in the basal and centromedial amygdala (CeM), respectively. Moreover, deletion of IgSF9b in the CeM of adult Nlgn2 knockout mice has a prominent anxiolytic effect. Our data place IgSF9b as a key regulator of inhibition in the amygdala and indicate that IgSF9b-expressing synapses in the CeM may represent a target for anxiolytic therapies.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Anti-MAGI-2 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
Anti-IGSF9B antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution